SEZ-HM106 | 价格

SEZ-HM106-100μg / 询价

SEZ-HM106-500μg / 询价

SEZ-HM106-500μgx2 / 询价

Human SEZ6 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Human SEZ6 Protein is expressed from HEK293 with His tag at the C-Terminus
It contains Leu20-His925 [Accession | Q53EL9-1].

分子量大小(Molecular Weight)

The protein has a predicted MW of 98.9 kDa. Due to glycosylation, the protein migrates to 145-150 kDa based on Bis-Tris PAGE result.

纯度(Purity)

> 95% as determined by Bis-Tris PAGE

内毒素(Endotoxin)

Less than 1 EU per μg by the LAL method.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Human SEZ6 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Immobilized Human SEZ6, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-SEZ6 Antibody, hFc Tag with the EC50 of 9.0 ng/ml determined by ELISA.

背景(Background)

Seizure-related protein 6 (Sez6) contributes to chronic pain development as sez6 knockout mice show attenuated pain behaviours after peripheral nerve injury, compared with control mice. The type I transmembrane isoform of Sez6 is cleaved by the β-amyloid precursor protein cleavage enzyme 1 (BACE1), resulting in Sez6 extracellular domain shedding from the neuron surface.

分子别名(Synonyms)

SEZ-6; SEZ6; BSRPC; BSRP-C

文献(References)

(1) Roitman M, Edgington-Mitchell LE, Mangum J, Ziogas J, Adamides AA, Myles P, Choo-Bunnett H, Bunnett NW, Gunnersen JM. Sez6 levels are elevated in cerebrospinal fluid of patients with inflammatory pain-associated conditions. Pain Rep. 2019 Mar 25;4(2):e719. doi: 10.1097/PR9.0000000000000719. PMID: 31041421; PMCID: PMC6455686.